These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6488735)

  • 1. Bayesian approaches in pharmacokinetic decision making.
    Schumacher GE; Barr JT
    Clin Pharm; 1984; 3(5):525-30. PubMed ID: 6488735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian and threshold probabilities in therapeutic drug monitoring: when can serum drug concentrations alter clinical decisions?
    Schumacher GE; Barr JT
    Am J Hosp Pharm; 1994 Feb; 51(3):321-7. PubMed ID: 8160684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using population-based serum drug concentration cutoff values to predict toxicity: test performance and limitations compared with Bayesian interpretation.
    Schumacher GE; Barr JT
    Clin Pharm; 1990 Oct; 9(10):788-96. PubMed ID: 2242660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Individualization of drug dosage by therapeutic monitoring in plasma and the application of pharmacokinetic principles].
    Klotz U
    J Clin Chem Clin Biochem; 1983 Nov; 21(11):649-58. PubMed ID: 6655441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.
    Sheiner LB
    Drug Metab Rev; 1984; 15(1-2):153-71. PubMed ID: 6745080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.
    Jelliffe RW; Schumitzky A; Van Guilder M; Liu M; Hu L; Maire P; Gomis P; Barbaut X; Tahani B
    Ther Drug Monit; 1993 Oct; 15(5):380-93. PubMed ID: 8249044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualization of drug dosage regimens.
    Platt DR
    Clin Lab Med; 1987 Jun; 7(2):289-99. PubMed ID: 3301171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.
    Steimer JL; Mallet A; Golmard JL; Boisvieux JF
    Drug Metab Rev; 1984; 15(1-2):265-92. PubMed ID: 6745083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primer on clinical pharmacokinetics.
    Bauer LA
    Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying decision analysis in therapeutic drug monitoring: using decision trees to interpret serum theophylline concentrations.
    Schumacher GE; Barr JT
    Clin Pharm; 1986 Apr; 5(4):325-33. PubMed ID: 3709081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring.
    Ried LD; McKenna DA; Horn JR
    Am J Hosp Pharm; 1989 May; 46(5):945-51. PubMed ID: 2729302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
    Cabelguenne D; Bleyzac N; Pivot C; Maire P
    Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying decision analysis in therapeutic drug monitoring: using receiver-operating characteristic curves in comparative evaluations.
    Barr JT; Schumacher GE
    Clin Pharm; 1986 Mar; 5(3):239-46. PubMed ID: 3514086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualized monitoring of the therapy with gentamycin using pharmacokinetic methods. Which method to choose?].
    Carvalho A; Fonseca C; Falcão F; Pereira TA; Freitas O; Parrinha A; Costa M; Rodrigues MJ; Ceia F; Luís AS
    Acta Med Port; 1996; 9(7-9):187-95. PubMed ID: 9005695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of limited laboratory-acquired therapeutic drug monitoring data in determining individualized drug requirements.
    Bachmann KA; Forney RB; Gronau G
    Ann Clin Lab Sci; 1987; 17(1):52-9. PubMed ID: 3579208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do heart failure specialist nurses think differently when faced with 'hard' or 'easy' decisions: a judgement analysis.
    Thompson C; Spilsbury K; Dowding D; Pattenden J; Brownlow R
    J Clin Nurs; 2008 Aug; 17(16):2174-84. PubMed ID: 18705737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.